BioSpace News Archive

Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced the appointment of Donna M. Cochener as General Counsel, Senior Vice President Legal.

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021.

Werewolf Therapeutics, Inc. announced the publication of two abstracts summarizing upcoming poster presentations at the American Association for Cancer Research Annual Meeting.

AbbVie (NYSE: ABBV) and Scripps Research, an independent, non-profit biomedical research and drug discovery institute, today announced a global collaboration to develop potential novel, direct-acting antiviral treatments for COVID-19.

AiM Medical Robotics, a leading developer of MRI-compatible intraoperative robotics for neurosurgery, today announced that it has raised $3.4 million in seed funding led by IQ Capital and Surrey Capital Partners.

BioLife Solutions, Inc., a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies and broader biopharma markets, provided additional details on its growth expectations for the Company’s SciSafe® biostorage services platform.

Wugen, Inc. today announced that the first patient has been dosed in a Phase 1/2 trial of WU-CART-007 for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL).

Inversago Pharma Inc. announced today the dosing of the first participant with metabolic syndrome in a Phase 1b clinical trial.

Agiliti Inc. (NYSE: AGTI) (“Agiliti”) today announced that the company will participate at the KeyBanc Life Sciences & MedTech Investor Forum on March 22, 2022.

Cortexyme, Inc. today announced the appointment of Marwan Noel Sabbagh, MD, FAAN, a board-certified neurologist and leading expert in Alzheimer’s and dementia care, to the company’s Board of Directors.